Business
DarioHealth Publishes Research Confirming the Impact of a Digital Therapeutic Platform and Live Coaching on Diabetes Outcomes
New Results Further confirm the Relationship Between Personalization and Outcomes NEW YORK,, May 27, 2021 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a
About this update from Dariohealth Corp.
[{"type":"text","content":"New Results Further confirm the Relationship Between Personalization and Outcomes\n\n\nNEW YORK,, May 27, 2021 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a pioneer in the global digital therapeutics market, today announced the publication of a new study through a Letter to the Editor in the Journal of Diabetes Science and Technology. The study is titled \"Digital Therapeutics for Type 2 Diabetes: Incorporating Coaching Support and Validating Digital Monitoring.\" \nPeople living with Type 2 diabetes have complicated self-care requirements that can make better health difficult to achieve. Although consumers have access to a wide variety of digital and app-based diabetes management tools, there is little clinical and self-reported evidence demonstrating the effectiveness of digital self-monitoring combined with coaching. \nIn this new study, participants using Dario's digital therapeutics for diabetes management were monitored for both clinical and self-reported impact. Over a period of three months, participants tracked blood glucose levels in the Dario app and worked with a live Certified Diabetes Care and Education Specialist (CDCES), leading to demonstrated clinically significant improvements on lab test results, platform-based data and self-reported data.\n This new research presents several key clinical data points: \n2.0% reduction in average HbA1c lab values for participants Significant reduction in additional lab values such as Fasting Blood Glucose (18%) and Body Mass Index (BMI) (10%) Statistically significant improvement in glucose variability Significant improvement in self-reported evaluation in weight and glucose control satisfactionFurther interaction analysis also indicated participant's engagement with a CDCES served to predict positive reductions in glucose variability in the following week, adding additional understanding of the impact of live coaching as a complement to digital self-monitoring.\n\"This clinical study re-confirms the persistent and substantial estimated HbA1c reductions we see in our other studies by demonstrating actual HbA1c reductions. The present study, while small, demonstrated a robust 2.0% reduction in measured HbA1c along with reductions in glucose variability,\" said Dr. Omar Manejwala, Chief Medical Officer of DarioHealth.\n\"These findings add valuable data to the little-under...